Theravance Biopharma, Inc. (TBPH) 股票分析

公司概述

Theravance Biopharma, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines within the United States, with a primary portfolio including YUPELRI, a once-daily nebulized long-acting muscarinic antagonist designed for the treatment of chronic obstructive pulmonary disease (COPD), alongside amprenloxtine as an investigational asset. The company functions within the broader Healthcare sector and specifically the Biotechnology industry, positioning itself as a specialized entity dedicated to advancing respiratory therapies and other medical interventions. As of the latest data, the firm possesses a market capitalization of $854.78M and reports annual trailing twelve-month revenue of $107.46M, supported by a workforce of 90 employees. These valuation and revenue figures indicate that Theravance Biopharma maintains a mid-cap profile, suggesting it is a mature yet still developing entity that balances established cash-generating capabilities with the ongoing capital requirements typical of the biotechnology industry to fund research and potential future commercialization efforts.

财务健康

The company reports a trailing twelve-month revenue of $107.46M and a net income of $105.89M, while its EBITDA stands at -$1,976,000, revealing a significant divergence where operational profitability before interest and taxes is negative despite substantial net earnings. This gap highlights a cost structure where non-operating income or significant tax benefits, potentially driven by the high profit margin of 98.5%, are offsetting the negative operating cash conversion metrics. The free cash flow is recorded at -$4,116,375, indicating that the company is currently burning cash to fund its operations and development pipeline rather than generating excess liquidity for expansion. However, the balance sheet remains robust with $315.36M in cash against total debt of $42.70M, resulting in a conservative debt-to-equity ratio of 14.39% which suggests a low leverage position relative to equity. Liquidity is exceptionally strong given the current ratio of 10.93, implying that the company holds more than ten times its current liabilities in current assets, providing ample short-term financial flexibility. Return on Equity is 44.8% while Return on Assets is -0.5%, a combination that reveals management is generating high equity returns likely due to a small asset base or significant non-operating income, though the negative ROA points to challenges in utilizing total assets efficiently for core operations.

估值评估

The stock trades with a trailing P/E ratio of 8.06 and a forward P/E of 12.25, implying that the market expects earnings growth to accelerate, as the forward multiple is significantly higher than the historical trailing multiple. The price-to-book ratio is 2.86, indicating that the market values the company at nearly three times its book value, which typically reflects expectations of superior future growth or intangible asset value not fully captured on the balance sheet. Alternative valuation metrics show a price-to-sales ratio of 7.95 and an EV/EBITDA of -294.60, suggesting that traditional earnings-based valuation is less relevant due to negative EBITDA, and investors are instead pricing the asset based on revenue potential and cash position. The 52-week high is $21.03 and the 52-week low is $8.09, placing the current implied price roughly in the middle to upper third of this range depending on recent fluctuations, though specific current price is not provided, the beta of 0.17 indicates the stock exhibits very low volatility relative to the broader market. This low beta suggests that the stock price moves less than the overall market, making it potentially less sensitive to general market swings but highly dependent on specific biotechnology sector developments.

Growth & Income

Revenue growth year-over-year stands at an impressive 144.7%, while earnings growth is listed as N/A, indicating that the substantial increase in sales is not yet fully translated into proportional earnings growth, likely due to the negative EBITDA and ongoing operational costs. As the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the firm reinvests all available earnings and cash flow back into research, development, and commercialization rather than distributing returns to shareholders. The absence of a dividend payout ratio confirms that the company prioritizes capital expenditure and pipeline advancement over shareholder income distribution, a common strategy for biotechnology firms in the growth phase. Overall, the growth profile is characterized by double-digit revenue expansion funded by a conservative balance sheet, while the income profile currently lacks shareholder distributions due to the company's focus on long-term asset development and market penetration in the respiratory disease space.